公开(公告)号：EP2190413B1

公开(公告)日：2015-01-28

申请号：EP08788414.4

申请日：2008-08-22

申请人： Stichting Het Nederlands Kanker Instituut ,  Slotervaart Participaties BV

发明人： BEIJNEN, Jacob, Hendrik ,  SCHELLENS, Johannes, Henricus, Matthias ,  MOES, Johannes ,  NUIJEN, Bastiaan

IPC分类号： A61K9/14 ,  A61K9/19 ,  A61K9/48 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K9/146 ,  A61K9/19 ,  A61K9/4858 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP2328555A2

公开(公告)日：2011-06-08

申请号：EP09785003.6

申请日：2009-08-24

申请人： Slotervaart Participaties BV ,  Stichting Het Nederlands Kanker Instituut

发明人： BEIJNEN, Jacob, Hendrik ,  SCHELLENS, Johannes, Henricus, Matthias ,  MOES, Johannes ,  NUIJEN, Bastiaan

IPC分类号： A61K9/14 ,  A61K9/19 ,  A61K9/48 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K9/19 ,  A61K9/141 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/4858 ,  A61K9/4866

摘要： Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant, wherein the substantially amorphous taxane is prepared by a solvent evaporation method and, in particular, spray drying. Methods of preparation of the composition and uses of the composition are also included.

公开(公告)号：EP2190413A2

公开(公告)日：2010-06-02

申请号：EP08788414.4

申请日：2008-08-22

申请人： Vereniging Het Nederlands Kanker Instituut ,  Slotervaart Participaties BV

发明人： BEIJNEN, Jacob, Hendrik ,  SCHELLENS, Johannes, Henricus, Matthias ,  MOES, Johannes ,  NUIJEN, Bastiaan

IPC分类号： A61K9/14 ,  A61K9/19 ,  A61K9/48 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K9/146 ,  A61K9/19 ,  A61K9/4858 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61K2300/00

摘要： Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included.